Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos RoviFRA:41L 89 5-Year Yield-on-Cost % is 8.95 as of Jul. 25, 2026, which is 48% above its 10-year median of 6.06. GuruFocus rates FRA:41L with a GF Score™ of 89/100 and a GF Value™ of €54.02 (Fairly Valued). The stock has 2 warning signs investors should review. Among 513 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 87.72% on this metric.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:41L'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.64 Med: 6.06 Max: 17.89
Current: 8.95
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest Yield on Cost was 17.89. The lowest was 1.64. And the median was 6.06.
FRA:41L's 5-Year Yield-on-Cost % is ranked better than 87.72% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs FRA:41L: 8.95
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Laboratorios Farmaceuticos Rovi 5-Year Yield-on-Cost % Related Terms
FRA:41L vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Laboratorios Farmaceuticos Rovi (FRA:41L) has a 5-Year Yield-on-Cost % of 8.95 as of Jul. 25, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 48% above median its historical median of 6.06. Over the past decade, Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % has ranged from 1.64 to 17.89. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #63 out of 513 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % too high?
Laboratorios Farmaceuticos Rovi's current 5-Year Yield-on-Cost % of 8.95 is 48% above median its 10-year median of 6.06. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 17.89. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.36. Laboratorios Farmaceuticos Rovi's value of 8.95 is 279.2% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #63 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #63 out of 513 companies for 5-Year Yield-on-Cost %. This places Laboratorios Farmaceuticos Rovi in the top 12% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.36. Laboratorios Farmaceuticos Rovi's value of 8.95 is 279.2% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own 5-Year Yield-on-Cost % has ranged from 1.64 to 17.89 over the past decade. While the company's 10-year median is 6.06 vs. the industry median of 2.36, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current 5-Year Yield-on-Cost % of 8.95 is 279.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current 5-Year Yield-on-Cost % is 8.95, which is 48% above median its own 10-year median of 6.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Fairly Valued. The stock's GF Value™ is €54.02, compared to a current price of €58.55 — trading 8.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 8.95, which is 48% above median its 10-year median of 6.06 and 279.2% above the Drug Manufacturers industry median of 2.36. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current 5-Year Yield-on-Cost % is 8.95 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €58.55 is trading 8.4% above its estimated GF Value™ of €54.02.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Fairly Valued.
Key valuation signals for FRA:41L:
5-Year Yield-on-Cost %: 8.95 (48% above median its 10-year median of 6.06)
GF Value™: €54.02 vs. price of €58.55 (8.4% above fair value)
Industry Position: 279.2% above the Drug Manufacturers median (#63 of 513)
No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score
Get the complete analysis for FRA:41L
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:41L has been successfully added to your 
